- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07613645
Lifestyle and Recurrent Clostridioides Difficile Infection (CDI)
Diet for Prevention of Recurrent C. Difficile Infection
This study aims to evaluate the impact of diet on the gut microbiome in adults with Clostridioides difficile infection (CDI). Eligible participants will be randomized and receive meals plus different types of health counseling. Counseling visits will be by phone or online videoconference (e.g. Zoom). Meals will be provided for two weeks and then participants will be asked to continue similar meals for 6 more weeks.
Participants will provide responses to questionnaires and multiple stool samples over the course of the study. The goal is to understand how different health factors might impact the risk of becoming infected again with C. difficile in the future.
Of note, this study will conceal the intervention details (type of diets) so that the control group does not increase their intake with the particular diet during the study. Participants in the control arm will be unblinded at the end of the study during a debrief with a member of the study team. At that time participants will be informed of diet being tested.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Inte tillämpbar
Kontakter och platser
Studiekontakt
- Namn: Kira Newman, MD, PhD
- Telefonnummer: 734-615-4628
- E-post: kinewman@med.umich.edu
Studieorter
-
-
Michigan
-
Ann Arbor, Michigan, Förenta staterna, 48109
- Rekrytering
- University of Michigan
-
Kontakt:
- Kira Newman, MD, PhD
- Telefonnummer: 734-615-4628
- E-post: kinewman@med.umich.edu
-
Huvudutredare:
- Kira Newman, MD, PhD
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Beskrivning
Inclusion Criteria:
- Provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and lifestyle considerations and availability for the duration of the study
- Non-recurrent non-fulminant CDI (laboratory-confirmed C. difficile infection without prior C. difficile infection within 3 months and no shock, hypotension, ileus, or megacolon)
- Currently receiving treatment or with plan to initiate treatment for CDI
- CDI treatment with standard regimen (fidaxomicin 200milligrams (mg) by mouth (PO) twice a day x 10-14 days or vancomycin 125mg PO 4 x a day (QID) x 10-14 days)
- No prior advanced therapy for C. difficile (i.e. prolonged antibiotic therapy, bezlotoxumab, fecal transplant, other microbial therapy)
Exclusion Criteria:
- Chemotherapy, immunotherapy, or transplant within 12 months
- Colon not in continuity (i.e. status post total colectomy or with current ileostomy)
- Medical comorbidities requiring specific fluid, sodium, or protein intake level outside range of prepared diet options
- Baseline diet with > 11grams fiber/1000 kilocalories
- Low sodium diet, vegan diet, gluten-free diet, Kosher diet or any other diet not able to be accommodated by the metabolic kitchen
- Allergies, food preferences, or other restrictions not able to be accommodated by the metabolic (note: lactose intolerance will not impact eligibility)
- Unwilling to stop probiotic supplements during the study period
- Current antibiotic therapy that will continue after CDI treatment has finished
- Hospitalized or in skilled nursing facility at time of CDI treatment conclusion
- Pregnancy or breast-feeding
- Unable to provide a stool sample of appropriate quality for further analysis (i.e. low volume, adulterated, delayed return, etc.)
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Förebyggande
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Enda
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Experimental Diet plus health counseling
As stated earlier, the diet and intervention details will not be listed for concealment purposes.
|
Participants will receive 2 weeks of prepared meals.
Participants will then be asked to follow a similar diet for 6 weeks.
|
|
Övrig: Diet (control diet per protocol) plus health counseling
As stated earlier, the diet and intervention details will not be listed for concealment purposes.
|
Participant will have two health counseling visits with a member of the study team between weeks 2-8.
Participants will receive 2 weeks of prepared meals.
Participants will then be asked to follow a similar diet for 6 weeks.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change from baseline to week 2 in alpha-diversity of fecal microbiome by 16S rRNA sequencing
Tidsram: Baseline, 2 weeks (post feeding period)
|
Change from baseline to week 2 (post feeding period) in alpha-diversity of fecal microbiome by 16S rRNA sequencing using Shannon index.
|
Baseline, 2 weeks (post feeding period)
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change from baseline to week 8 in microbiome alpha-diversity (Shannon Index via 16S rRNA)
Tidsram: baseline to week 8
|
Measured by Shannon Index via 16S rRNA.
|
baseline to week 8
|
|
Incidence of recurrent CDI
Tidsram: baseline to week 8
|
Laboratory-confirmed symptomatic infection requiring treatment.
|
baseline to week 8
|
|
Change in CDI-related Quality of Life (QOL) baseline to Week 8
Tidsram: Baseline to Week 8
|
Patient-reported health-related quality of life assessed using the Clostridioides difficile Quality of Life Survey (Cdiff32) total score (range 0-100; higher scores indicate better quality of life).
|
Baseline to Week 8
|
|
Tolerability of diet based on the mean percent of meals consumed during the first 2 weeks
Tidsram: 2 weeks (during the provided meal period)
|
This is during the 2-weeks of receiving provided meals.
|
2 weeks (during the provided meal period)
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: Kira Newman, MD, PhD, University of Michigan
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- HUM00284257
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .